Valiant Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Valiant Laboratories Ltd reported a 43.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 118.8%.
• Its expenses for the quarter were up by 26.2% QoQ and 106.0% YoY.
• The net profit decreased 246.8% QoQ and decreased 456.9% YoY.
• The earnings per share (EPS) of Valiant Laboratories Ltd stood at 0.4 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Valiant Laboratories Ltd is a company whose specific products, services, and industry are not detailed in the provided data. Therefore, no assumptions can be made regarding its primary business operations or recent major developments. Without additional context or external sources, it remains unclear what market segment Valiant Laboratories Ltd operates in or if there have been any significant changes or strategic initiatives recently undertaken by the company.

Revenue

In the first quarter of fiscal year 2026 (Q1FY26), Valiant Laboratories Ltd reported a total income of ₹47.48 crores. This represents a substantial quarter-over-quarter (QoQ) increase of 43.5% from the previous quarter (Q4FY25), where the total income was ₹33.09 crores. Additionally, there is a significant year-over-year (YoY) growth of 118.8% from the same quarter in the previous year (Q1FY25), which recorded total income of ₹21.70 crores. The data highlights a noteworthy upward trend in total income over both QoQ and YoY periods.

Profitability

Valiant Laboratories Ltd reported a profit before tax of ₹2.45 crores in Q1FY26, marking a turnaround from a loss of ₹2.57 crores in Q4FY25 and an improvement from a loss of ₹0.16 crores in Q1FY25. The profit after tax for Q1FY26 was ₹1.82 crores, compared to a loss after tax of ₹1.24 crores in Q4FY25 and a loss of ₹0.51 crores in Q1FY25. This change is reflected in the earnings per share (EPS), which improved to ₹0.40 in Q1FY26 from a negative ₹0.30 in Q4FY25 and a negative ₹0.10 in Q1FY25. The data indicates a significant improvement in profitability metrics both on a QoQ and YoY basis.

Operating Metrics

The total expenses for Valiant Laboratories Ltd in Q1FY26 totaled ₹45.02 crores, which is a 26.2% increase from ₹35.66 crores in Q4FY25 and a 106.0% increase from ₹21.85 crores in Q1FY25. The tax expense for Q1FY26 was ₹0.63 crores, a shift from a tax benefit of ₹1.33 crores in Q4FY25 and an increase from ₹0.35 crores in Q1FY25. These figures show an increase in operating expenses and tax obligations over both the QoQ and YoY periods. However, specific ratios such as P/E ratio, debt-to-equity ratio, or current ratio cannot be calculated with the provided data.